“…Eisman reported 1,25-dihydroxyvitamin D 3 receptor existed in human breast cancer cells firstly, which inspired people to explore the anti-cancer effect of vitamin D (Eisman et al, 1986). But the excessive β-carotene may lead the body to a high oxidation state (Marques et al, 2004), which harmful to health, and while 1,25-dihydroxyvitamin D 3 is a promising material with anti-tumor activity, excessive 1,25-dihydroxyvitamin D 3 could also easily induce hypercalcemia (Iqbal et al, 2003). β-carotene and 1,25-dihydroxyvitamin D 3 in combination could not only reduce the amount of β-carotene, but also reduce the amount of 1,25-dihydroxyvitamin D 3 , thus reducing their pharmaceutical concentration, their toxic effects and the resistance of tumor cells, so the combination of these two agents is a new research direction of prevention and treatment of cancer.…”